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merging Blood Biomarkers to
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otirios Tsimikas, MD, FACC,* James T. Willerson, MD, FACC,† Paul M. Ridker, MD, FACC‡
an Diego, California; Houston, Texas; and Boston, Massachusetts
Several emerging plasma biomarkers may ultimately prove useful in risk stratification and
prognosis of cardiovascular disease. The clinical utility of these biomarkers will depend on
their ability to provide a reflection of the underlying atherosclerotic burden or activity; the
ability to provide reliable, accurate, and cost-effective information; and the ability to predict
future events. High-sensitivity C-reactive protein (hs-CRP) fulfills many, if not all, of these
criteria, and blood levels of hs-CRP are now commonly used in clinical practice to improve
vascular risk prediction in primary and secondary prevention across all levels of low-density
lipoprotein-cholesterol (LDL-C), all levels of the Framingham Risk Score, and all levels of
metabolic syndrome. High-sensitivity C-reactive protein may also have clinical relevance as
an adjunct to LDL-C for both the targeting and monitoring of statin therapy. Accumulating
evidence suggests that several other selected emerging biomarkers may also potentially prove
useful in the diagnosis and prognosis of cardiovascular disease. Specifically, data are
accumulating on the potential clinical utility of lipoprotein-associated lipoprotein-associated
phospholipase A2, myeloperoxidase, oxidized LDL, lipoprotein (a), isoprostanes, and small,
dense LDL. This review focuses on hs-CRP and these emerging plasma biomarkers, and
their potential diagnostic and prognostic utility in cardiovascular disease. Plasma biomarkers
that reflect the clinical potential of atherothrombotic disease may allow more precise risk
stratification and prognostication in high-risk populations, and perhaps earlier diagnosis and
intervention in patients at risk for or with occult cardiovascular disease. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.0662006;47:C19–31) © 2006 by the American College of Cardiology Foundation
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Liomarkers are generally considered to be plasma measure-
ents of molecules, proteins, or enzymes that provide inde-
endent diagnostic or prognostic value by reflecting an under-
ying disease state or condition. In the case of coronary heart
isease, they must reflect the underlying biology of the
essel wall and, in particular, the atherosclerotic process
nd/or its sequelae. The clinical utility of a biomarker
epends on its ability to account for a significant proportion
f the disease being evaluated; be accurate and reliable;
rovide good sensitivity, specificity, and predictive value;
nd be available for widespread application (1). Clinical
pplication further requires the demonstration, in multiple
rospective cohorts, that evaluation of the biomarker is not
nly predictive of disease, but substantively adds to tradi-
ional risk factors such as those used in the Framingham risk
core. This review evaluates several selected blood-based
iomarkers that have the potential for being clinically useful
n assessing cardiovascular risk.
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ccepted October 25, 2005.OW-DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C)
S A BIOMARKER OF CARDIOVASCULAR RISK
istorically, the cholesterol content of lipoproteins, and in
articular LDL-C, is the prototypical biomarker of coronary
rtery disease (CAD). Cholesterol content of lipoproteins
erves as a convenient, yet inadequate, surrogate marker for
uantitating concentrations of specific lipoproteins. It was
ppreciated in 1903 by Anitschkow that feeding rabbits
urified cholesterol resulted in typical atherosclerotic le-
ions, which were postulated to occur by entrance of plasma
holesterol into the vessel wall (reviewed in reference [2]).
he most convincing clinical evidence that elevated LDL-C
s causal in the pathogenesis of CAD comes from patients
ith homozygous familial hypercholesterolemia, who usu-
lly have LDL-C levels of 500 mg/dl, where myocardial
nfarction and ischemic death have been reported in the first
ecade of life (3). Cholesterol analysis was first reported in
885 (4), but it was not until 1974 that a fully enzymatic
rocedure using cholesterol esterase and oxidase coupled to
colorimetric agent became widely available clinically (5).
ronically, until just recently, most values of LDL-C in
linical laboratories were not directly measured, because of
he complexities of separating various lipoprotein fractions,
ut were actually estimated from the Friedewald formula.
ven measures of direct LDL-C contain the cholesterol
ontent of lipoprotein (a) (Lp[a]), which may be significant
n patients with high Lp(a) levels. Despite these limitations,
DL-C has been consistently confirmed as a major risk
actor for CAD and is the basis for treatment with statins.
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Biomarkers in Vulnerable Patients April 18, 2006:C19–31Nonetheless, lipoproteins alone do not explain all of the
isk inherent in CAD; one-half of all heart attacks and
trokes occur among individuals without hypercholesterol-
mia as currently defined, and one-fifth of all cardiovascular
vents occur in the absence of any of the major risk factors
6). Thus, additional biomarkers are needed to more fully
nd non-invasively diagnose and prognosticate CAD.
IGH-SENSITIVITY C-REACTIVE PROTEIN (hs-CRP)
-reactive protein is a circulating pentraxin that plays a
ajor role in the human innate immune response (7) and
rovides a stable plasma biomarker for low-grade systemic
nflammation. C-reactive protein is produced predomi-
antly in the liver as part of the acute phase response.
owever, CRP is also expressed in smooth muscle cells
ithin diseased atherosclerotic arteries (8) and has been
mplicated in multiple aspects of atherogenesis and plaque
ulnerability, including expression of adhesion molecules,
nduction of nitric oxide, altered complement function, and
nhibition of intrinsic fibrinolysis (9,10).
Abbreviations and Acronyms
ACS  acute coronary syndrome
apo  apolipoprotein
CAD  coronary artery disease
CETP  cholesterol ester transfer protein
ELISA  enzyme-linked immunoabsorbent assay
HDL-C  high-density lipoprotein cholesterol
HOCl  hypochlorous acid
hs-CRP  high-sensitivity C-reactive protein
LDL-C  low-density lipoprotein cholesterol
Lp(a)  lipoprotein (a)
Lp-PLA2  lipoprotein-associated phospholipase A2
MPO  myeloperoxidase
OR  odds ratio
OxLDL  oxidized LDL
OxPLs  oxidized phospholipids
PAF-AH  platelet-activating factor acetylhydrolase
PCI  percutaneous coronary interventionigure 1. Additive value of high-sensitivity C-reactive protein after adjustment
ipoprotein (LDL) cholesterol (right) and across all levels of calculated FraminAmong patients with stable angina and established CAD,
lasma levels of hs-CRP have consistently been shown
ssociated with recurrent risk of cardiovascular events (11–
3). Similarly, during acute coronary ischemia, levels of
s-CRP are predictive of high vascular risk even if troponin
evels are non-detectable, suggesting that inflammation is
ssociated with plaque vulnerability even in the absence of
etectable myocardial necrosis (14–16). The ability of
s-CRP to predict vascular risk has also been consistently
emonstrated among patients undergoing elective angio-
lasty as well as surgical coronary revascularization (17,18),
nd the clinical combination of hs-CRP, troponin, and
rain natriuretic peptide has been advocated as a generalized
eans to risk stratification (19).
Despite these data, the most relevant use of hs-CRP
emains in the setting of primary prevention. To date, over
wo dozen large-scale prospective studies have shown base-
ine levels of hs-CRP to independently predict future
yocardial infarction, stroke, cardiovascular death, and
ncident peripheral arterial disease (20,21). Moreover, eight
ajor prospective studies have had adequate power to
valuate hs-CRP after adjustment for all Framingham
ovariates, and all have confirmed the independence of
s-CRP (22–28). For example, in the Women’s Health
tudy (23), baseline levels of hs-CRP classified as 1, 1 to
, and 3 mg/l have been shown to provide important
rognostic information on risk across all levels of LDL-C
Fig. 1, right) and all levels of the Framingham Risk Score
Fig. 1, left). As shown in Figure 2, the poorest event-free
urvival in this cohort was, as expected, among those with
levated levels of both LDL-C and hs-CRP. However, as
lso shown in Figure 2, cardiac event-free survival was worse
or those with elevated levels of hs-CRP and low levels of
DL-C as compared to those with elevated levels of
DL-C and low levels of hs-CRP. More recent analyses
rom this cohort further demonstrate the additive value of
s-CRP across all levels of the total cholesterol to high-
ensity lipoprotein cholesterol (HDL-C) and apolipopro-for traditional risk factors. Data are shown across all levels of low-density
gham Risk (left). Adapted, with permission, from Ridker et al. (23).
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April 18, 2006:C19–31 Biomarkers in Vulnerable Patientsein (apo)B to apoA ratios, even after adjustment for age,
moking, blood pressure, obesity, and diabetes (29). Similar
ata are now available from the Physicians Health Study
22), the Atherosclerosis Risk in Communities (ARIC)
tudy (25), the Nurses Health Study and Health Profes-
ionals Follow-Up Studies (24), the MONItoring of Trends
nd Determinants in CArdiovascular Disease (MONICA)-
ugsberg cohort (26), the Reykjavik Heart Study (27), the
oronary Heart Study (28), and even the Framingham
ohort, at least with regard to stroke (30). Multiple cohort
tudies further indicate that hs-CRP provides additive risk
nformation across all levels of the metabolic syndrome
31–33) and is predictive of incident type 2 diabetes (34,35).
Beyond CRP’s ability to predict risk among both primary
nd secondary prevention patients, interest in it has in-
reased with the recognition that statins lower CRP in a
anner largely independent of LDL-C reduction (36–38)
nd that the efficacy of statin therapy may be related to the
nderlying level of vascular inflammation as detected by
s-CRP. This phenomenon, first observed within the Cho-
esterol and Recurrent Events trial of secondary prevention
11), has since been observed within the Air Force/Texas
oronary Atherosclerosis Prevention Study of primary pre-
ention (39) and, most recently, among acute coronary syn-
rome (ACS) patients enrolled in the Pravastatin or Atorva-
tatin Evaluation and Infection Therapy–Thrombolysis In
yocardial Infarction 22 (PROVE IT–TIMI 22) trial (40). In
his latter study, the level of hs-CRP achieved after initia-
ion of statin therapy proved to be of equal importance for
ubsequent vascular events as was the achieved level of
DL-C. However, the best overall survival was observed
mong those who not only lowered LDL-C below 70
g/dl, but who also lowered hs-CRP below 2 mg/l (Fig. 3).
his effect was present regardless of the statin regimen used.
urther, because the level of hs-CRP achieved after initia-
igure 2. Cardiovascular event-free survival in apparently healthy Ameri-
an women according to plasma levels of low density lipoprotein (LDL)-
holesterol and high sensitivity C-reactive protein (CRP). Adapted, with
ermission, from Ridker et al. (23).ion of statin therapy could not be predicted by the level of
A
dDL-C, these data have lead to the hypothesis that mea-
uring and monitoring of hs-CRP following initiation of
tatin therapy may be required to maximize benefit in a
anner analogous to the way clinicians currently measure
nd monitor LDL-C (40). Support for this concept is
rovided by data from the Reversal of Atherosclerosis With
ipitor (REVERSAL) trial, in which atherosclerotic pro-
ression defined by intravascular ultrasound was reduced
ore when levels of both hs-CRP and LDL-C were
owered (41). Indeed, in the REVERSAL data for athero-
clerotic regression, as in the PROVE IT–TIMI 22 data for
linical events, the greatest benefits were observed among
hose who not only achieved the lowest levels of LDL-C,
ut who also achieved the lowest levels of hs-CRP.
Despite the evidence described above, it is important to
ecognize that there remain no firm data to date that
owering CRP levels per se will lower vascular risk. Further,
s with other biomarkers of inflammation, it remains
ontroversial whether CRP plays a direct causal role in
therogenesis (42), and ongoing work with targeted CRP-
owering agents will be required to fully test this hypothesis.
owever, the clinical utility of hs-CRP has been well
stablished, and on the basis of data available through 2002,
he Centers for Disease Control and Prevention and the
merican Heart Association endorsed the use of hs-CRP as
n adjunct to global risk prediction, particularly among
hose at “intermediate risk”(43). Those guidelines also
uggested use of hs-CRP for risk stratification in the setting
f acute ischemia and for secondary prevention. Data
vailable since 2002 strongly reinforce these recommenda-
ions and suggest expansion to lower-risk groups, as well as
hose taking statin therapy. Perhaps most importantly, data
or hs-CRP provides evidence that biomarkers beyond those
raditionally used for vascular risk detection and monitoring
an play important clinical roles in prevention and treatment.
igure 3. Rates of recurrent myocardial infarction and cardiovascular death
mong acute coronary syndrome patients treated with statin therapy
ccording to achieved levels of low density lipoprotein (LDL)-cholesterol
nd high sensitivity C-reactive protein (CRP) in the Pravastatin or
torvastatin Evaluation and Infection Therapy–Thrombolysis In Myocar-
ial Infarction 22 trial. Adapted, with permission, from Ridker et al. (40).
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Biomarkers in Vulnerable Patients April 18, 2006:C19–31IPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2
ipoprotein-associated phospholipase A2 (Lp-PLA2), also
nown as platelet-activating factor acetylhydrolase (PAF-
H), hydrolyzes sn-2 side chains of oxidized phospholipids
OxPLs) to yield a free oxidized fatty acid and lysophos-
hatidylcholine (Fig. 4). This activity creates two potentially
ro-inflammatory and pro-atherogenic particles from one,
lthough it has not been determined if this is a proathero-
enic or anti-atherogenic property (44). Lipoprotein-
ssociated phospholipase A2 is secreted by monocyte-
acrophages, T-cells, and mast cells, and has high affinity,
esides in, and is transported by lipoproteins. It is primarily
resent on LDL, and small amounts are found on HDL,
ut it also seems to have a particular predilection for binding
o Lp(a), where it is found in up to seven times higher
ontent than equimolar amounts of LDL (45). The phos-
holipase activity of HDL was recently shown to be entirely
ue to Lp-PLA2 rather than paraoxonase, suggesting that
p-PLA2 accounts for the anti-atherogenic and anti-
nflammatory properties of HDL (46). Several studies have
hown protective effects of overexpression of PAF-AH,
ncluding resistance against oxidative stress (47), reduced
evels of oxidized lipoproteins (48), and a reduction in
therosclerosis (49). Interestingly, in Japanese populations,
n inherited deficiency of Lp-PLA2, present as a heterozy-
ous trait in 27% of the population, appears to confer
ncreased risk of myocardial infarction, stroke, and periph-
ral arterial disease (50). However, other data suggest that it
ay be pro-atherogenic, as it is present within atheroscle-
otic plaques and co-localizes with macrophages (51). An-
mal studies suggest that inhibitors of Lp-PLA2, interest-
ngly, may confer protection against atherosclerosis (52),
nd phase II studies are currently under way to test such
ompounds in humans.
Recently, an antibody-based sandwich enzyme-linked
mmunoabsorbent assay (ELISA) has been developed to
igure 4. The role of lipoprotein-associated phospholipase A2 (Lp-PLA2)
acphee (44). LDL  low-density lipoprotein; oxLDL  oxidized low-easure Lp-PLA2 levels in plasma. This plasma mass assay shows a high correlation with Lp-PLA2 activity. Several
rospective epidemiological studies have reported that Lp-
LA2 is a predictor of CAD, although controversy persists
s to its independence from LDL-C. The relationship of
p-PLA2 to LDL-C is also supported by several studies
howing equivalent decreases in Lp-PLA2 and LDL-C
evels in response to several different classes of lipid-
owering agents (53). Further, in contrast to CRP, which is
educed by statin therapy in a manner independent of effects
n LDL-C, there is little evidence that statins lower
p-PLA2 once LDL-C reduction is accounted for (54).
onetheless, in a nested case-control study of hyperlipid-
mic patients from the West of Scotland Coronary Preven-
ion Study (WOSCOPS), elevated baseline Lp-PLA2 levels
ere found to be independent predictors of death, myocar-
ial infarction, and revascularization in males, although the
dds ratio (OR) was only 1.2 (55). In the ARIC study,
p-PLA2 was an independent predictor of incident CAD,
ut only in patients with LDL-C levels below 130 mg/dl
25), an observation that conflicts somewhat with that from
he WOSCOPS data. In the MONICA study, Lp-PLA2
evels predicted hard coronary events in hypercholester-
lemic middle-aged males at 14-year follow-up (56). In this
tudy, LDL-C was not measured and thus, the indepen-
ence of Lp-PLA2 to LDL-C could not be evaluated.
rilakis et al. (57) recently showed that elevated Lp-PLA2
t baseline in patients undergoing clinically indicated coro-
ary angiography predicted cardiovascular events at four-
ear follow-up, independent of traditional risk factors and
RP. In that study, Lp-PLA2 did not correlate with
ngiographic CAD, suggesting it might be more involved in
AD progression or plaque destabilization. However, in a
ase-control analysis from the Women’s Health Study (58),
p-PLA2 was not an independent predictor of cardiac
vents after adjusting for LDL-C levels. In all of the above
e breakdown of oxidized phospholipids. Reprinted, with permission, from
y lipoprotein.tudies, the predictive value of Lp-PLA2 was attenuated
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April 18, 2006:C19–31 Biomarkers in Vulnerable Patientsubstantially after adjusting for LDL-C and traditional risk
actors.
The current data support continued research evaluating
p-PLA2 as a potential predictor of cardiovascular disease.
n particular, further evidence is needed to quantitate the
xtent to which Lp-PLA2 measures are independent of
raditional risk factors, particularly LDL-C. In addition,
dditional data are needed in more diverse populations, as
ost of the data are derived from middle-aged males.
YELOPEROXIDASE (MPO)
yeloperoxidase is a heme peroxidase that is present in and
ecreted by activated phagocytes at sites of inflammation.
yeloperoxidase can generate several reactive, oxidatively
erived intermediates, all mediated through a reaction with
ydrogen peroxide, to induce oxidative damage to cells and
issues. For example, MPO reacts with hydrogen peroxide
nd chloride anion at physiological concentrations to pro-
uce hypochlorous acid (HOCl), a potent metal ion-
ndependent chlorinating oxidant that can lead to formation
f chlorotyrosine and other chlorinated products, resulting
n adverse biological effects (59). Myeloperoxidase can also
nduce formation of tyrosyl radicals, resulting in dityrosine
nd generation of nitrotyrosine and nitrated lipids through
eactions of hydrogen peroxide and nitric oxide, leading to
onsumption of nitric oxide and nitric-oxide derived oxi-
ants in vitro and in vivo. Oxidation products from MPO
re found at significantly increased rates (up to 100-fold
igher compared to circulating LDL) on LDL isolated from
therosclerotic lesions (60) and lead to accelerated foam-cell
ormation through nitrated apoB-100 on LDL and uptake
y scavenger receptors (61). Such distinct products of MPO
re also clearly documented within lipid-rich, foam-cell-rich
reas of human atherosclerotic lesions (62). More recently,
everal studies have shown that HDL is susceptible to
xidative modification with MPO-mediated nitration, chlo-
ination, and tyrosilation. Such modified HDL levels were
igher in patients than in control subjects, were present within
therosclerotic lesions, and resulted in decreased cholesterol
fflux out of cells via an ABCA1-mediated mechanism, impli-
ating oxidized HDL as an additional mechanism of lesion
ormation (63–65).
Accumulating evidence suggests that MPO may play a
ausal role in plaque vulnerability (66) (Fig. 5). Sugiyama
t al. (67) showed that advanced ruptured human athero-
clerotic plaques, derived from patients with sudden cardiac
eath, strongly expressed MPO at sites of plaque rupture, in
uperficial erosions and in the lipid core, whereas fatty
treaks exhibited little MPO expression. In addition, MPO
acrophage expression and HOCl were highly colocalized
mmunochemically in culprit lesions of these patients. Sev-
ral inflammatory triggers, such as lysophosphatidylcholine,
holesterol crystals, and CD40 ligand, induced release of
PO and HOCl production from MPO-positive macro-
hages in vitro. In an in vitro study, HOCl induced mndothelial cell death and tissue factor expression, suggest-
ng a link between endothelial erosion and thrombosis (68).
here is also evidence that neutrophils, which secrete
PO, infiltrate fissured and thrombosed plaques in patients
ith ACSs (69). Consistent with MPO’s potential role in
he atherosclerotic process, genetic polymorphisms resulting
n MPO deficiency or diminished activity are associated
ith lower cardiovascular risk, although the generalizability
f these findings is uncertain (70,71).
In parallel with MPO’s effects on nitric oxide, LDL
xidation, and presence within ruptured plaques, several
ecent clinical studies have suggested that MPO levels may
rovide diagnostic and prognostic data in endothelial func-
ion, angiographically determined CAD, and ACSs. Serum
evels of MPO were recently noted to independently predict
rachial artery flow-mediated dilation in 298 subjects with
AD or multiple risk factors for CAD (72). In a case
ontrol study of 175 patients with angiographically deter-
ined CAD, Zhang et al. (73) showed that the highest
uartiles of both blood and leukocyte MPO levels were
ssociated with ORs of 11.9 and 20.4, respectively, for the
resence of CAD compared to the lowest quartiles. In the
7E3 Anti-Platelet Therapy in Unstable Refractory Angina
tudy, Baldus et al. (74) showed that MPO levels were
trong independent predictors of increased risk for subse-
uent cardiovascular events at six months in patients with
CSs and seemed to particularly identify patients at higher
isk initially presenting with low troponin T levels. In this
CS study, the combination of CRP and MPO appeared to
rovide better prognostic information then either used
lone. Brennan et al. (75) obtained MPO levels in the
mergency department in 604 patients presenting with chest
ain but no initial evidence of myocardial infarction, and
howed that MPO levels predicted the in-hospital develop-
igure 5. The role of myeloperoxidase in plaque vulnerability. Reprinted,
ith permission, from Hazen (66). HOCl  hypochlorous acid; MPO 
yeloperoxidase; mRNA  messenger ribonucleic acid.ent of myocardial infarction, independent of other mark-
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Biomarkers in Vulnerable Patients April 18, 2006:C19–31rs of inflammation, such as CRP. In addition, they showed
hat MPO levels were strong predictors of death, myocar-
ial infarction, and revascularization at six months after the
nitial event. Interestingly, atorvastatin has been shown to
educe levels of MPO-derived oxidants, independent of the
ipid-lowering effects, suggesting specific antioxidant prop-
rties (76,77).
The current data suggest that MPO may serve as both a
arker of disease, providing independent information on
iagnosis and prognosis of patients with chest pain, and also
s a potentially causal entity in the progression and desta-
ilization of atherosclerotic lesions at the time of acute
schemia. It is not yet clear how much additional predictive
ower MPO levels provide above and beyond standard
schemia markers such as troponin, and further work is
equired to develop a commercial standardized assay. More-
ver, as outlined above, almost all data for MPO is in the
etting of ACS or established CAD, so the ability of MPO
o provide information beyond traditional atherothrombotic
isk factors used in the Framingham Risk Score is unknown.
dditional studies are also needed to confirm its diagnostic
nd prognostic ability.
XIDIZED LDL (OxLDL)
xidized LDL is generated during lipid peroxidation when
xygen free radicals abstract a hydrogen atom (H) from a
ethylene (CC) carbon present on polyunsaturated fatty
cids, resulting in generation of reactive species that modify
oth the lipid and protein components of LDL (as well as
ystander proteins). Oxidation of LDL occurs primarily in
he vessel wall, activating many inflammatory and athero-
enic pathways (78,79).
Oxidized LDL is not present in normal arteries and is
resent only in markedly diminished amounts in fibrotic or
egressing lesions (80). However, it is present in almost all
ther lesion types, including very early lesions of fetal aortas
hose mothers were hypercholesterolemic during gestation
ven before monocyte entry into the vessel wall, suggesting
hat LDL oxidation is involved a priori in the development
f atherosclerotic lesions (81). Human carotid and coronary
rteries are significantly enriched in OxLDL and, impor-
antly, unstable plaques appear to be preferentially enriched
n OxLDL (82,83). In animals, OxLDL within plaques is
referentially depleted in response to regression/antioxidant
iets (84–86), and in humans OxLDL becomes depleted
fter treatment with statins (87). In addition, OxLDL may
e imaged in the vessel wall of animal models using
adiolabeled oxidation-specific antibodies (84,88,89).
Oxidized LDL is not one homogeneous entity, but
epresents multiple chemical and immunogenic modifica-
ions of the lipid and apoB-100 on LDL. The term
OxLDL” has been used in a generic sense to describe many
ifferent types of OxLDL. To improve clarity in this rapidly
volving field of OxLDL biomarkers, we have suggested
hat investigators designate the particular type of OxLDL
F
lhey describe with the antibody used to detect it (i.e.,
xLDL-E06 measures OxPL epitopes on apoB using the
urine antibody E06) (90–92).
Currently, three major OxLDL plasma ELISAs have been
eveloped based on murine monoclonal antibodies DLH3,
E6, and E06 that recognize various epitopes of OxLDL.
ntibody DLH3 detects oxidized phosphatidylcholine
pitopes on LDL and is generally performed on isolated LDL,
hich is not amenable to high-throughput sample measure-
ent (OxLDL-DLH3) (93). Antibody 4E6 binds to a deri-
atized apoB moiety when at least 60 lysine groups have been
odified, but it binds to both copper OxLDL and to
alondialdehyde-LDL (OxLDL-4E6). Oxidized LDL-4E6
s available commercially for research purposes as a sandwich
LISA. A high correlation has been noted between OxLDL-
E6 and LDL-C (r 0.65 to 0.70) in several studies (94–97).
he natural murine antibody E06 specifically binds to the
hosphorylcholine head group of oxidized but not native
hospholipids (91,92,98,99) to measure OxLDL-E06. This
ssay is performed by capturing a constant, saturating amount
f each patient’s plasma apoB-100 on a microtiter plate with
urine antibody MB-47, which specifically binds human
poB-100. Because each plate binds an equal fraction of each
atient’s apoB-100, it is by definition independent of LDL-C.
iotinylated E06 is then added to detect the presence of
xPL, e.g., to yield OxPL/apoB (Fig. 6). This assay is
urrently not standardized to absolute units of OxPL and is
ead out in relative light units per 100 ms with chemilumines-
ent techniques.
In the last five years, an increasing number of studies have
valuated the role of OxLDL in pre-clinical atherosclerosis,
ndothelial dysfunction, stable CAD, ACS, percutaneous
oronary intervention (PCI), and response to statins. Ele-
ated plasma OxLDL levels have been associated with
ncreased carotid intima-media thickness in asymptomaticigure 6. Schematic representation of the chemiluminescent enzyme-
inked immunoabsorbent assay to measure oxidized LDL-E06.
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April 18, 2006:C19–31 Biomarkers in Vulnerable Patientsubjects with relatives with familial hypercholesterolemia,
symptomatic middle-aged males, and even in children
97,100–102). Increased OxLDL levels have been recently
ssociated with the metabolic syndrome and small, dense
DL (94,95,103). Coronary and brachial endothelial func-
ion is strongly correlated with plasma OxLDL levels
104–106), and improvement of brachial endothelial func-
ion was strongly correlated with reduced plasma OxLDL-
LH3 levels after LDL apheresis (107).
Oxidized LDL plasma levels correlate with the presence
f CAD (92,95,108). Toshima et al. (108) have shown that
lasma OxLDL-DLH3 levels were elevated in patients with
AD compared to normal control subjects, and that the
eceiver operating curves showed that the area under the
urve was higher for OxLDL-DLH3 than for total choles-
erol, apoB, HDL-C, and triglyceride levels (108). Simi-
arly, Holvoet et al. (95) also showed that OxLDL-4E6
evels were higher in older (mean age 74 years) patients with
AD, CAD-risk equivalent, and the metabolic syndrome.
xidized LDL-4E6 correlated with CRP and hypercholes-
erolemia, which likely explains why subjects with CAD had
ower levels of OxLDL-4E6 than those with CAD-risk
quivalents, since they also had lower LDL-C levels after
reatment. Our group recently demonstrated that OxLDL-
06 strongly correlated with the presence and extent of
AD and was an independent predictor of CAD in a
odel with all traditional risk factors, including LDL-C
nd CRP (92).
Similarly, elevated OxLDL levels are significantly higher
n patients with ACS (82,98,109). Oxidized LDL-4E6
redicted the presence of ACS in conjunction with troponin
evels; OxLDL-DLH3 appeared to differentiate the severity
f the underlying clinical presentation, and plasma levels
ere correlated with the presence of immunochemically
etected OxLDL in coronary atherectomy specimens; and
xLDL-E06 levels showed significant increases in patients
fter acute myocardial infarction and subsequently declined
ear basal levels by seven months, confirming a temporal
ise and fall of OxLDL due to plaque rupture and/or
nfarction. These studies emphasize that in a setting of
laque disruption and myocardial infarction, these values
ill be elevated, reflecting an acute phase response, and
annot be used to ascertain baseline values.
Our group has also shown that OxLDL-E06 levels
ignificantly increased immediately after PCI and returned
o baseline by 6 h (99), suggesting iatrogenically induced
fflux of OxPL from the treated plaque. Oxidized LDL
utoantibody titers decreased and apoB-immune complex
evels increased acutely in a classical anamnestic immuniza-
ion pattern, consistent with release of OxLDL and binding
y pre-formed autoantibodies and generation of immune
omplexes. We have also shown recently that statins affect
xLDL-E06 levels. In the Myocardial Ischemia Reduction
ith Aggressive Cholesterol Lowering Study, levels of total
poB-associated OxPL were significantly reduced in the ator-
astatin group (91). However, despite a smaller pool of apoB, mhe content of OxPL in the remaining individual apoB
articles (OxPL/apoB) was increased and associated with
ncreased Lp(a) levels, which we have recently shown bind
uch OxPL (98,99,110). This suggests the hypothesis that
obilization of OxPL, binding to Lp(a), and ultimate
learance represents a novel mechanism contributing to
apid plaque stabilization induced by atorvastatin.
Three recent studies assessed the prognostic utility of
xLDL measures. In a cross-sectional study, Holvoet et al.
111) showed that OxLDL-4E6 levels did not predict
verall coronary heart disease, but did predict incident
yocardial infarction in an older cohort. In a prospective
tudy, Shimada et al. (112) followed 238 patients with CAD
or a mean of 52 months and showed that baseline levels of
xLDL-DLH3 were significantly higher in patients with
ubsequent development of cardiac death, non-fatal myo-
ardial infarction, and unstable angina. In a multivariate
nalysis accounting for typical risk factors, including
DL-C, an independent association of OxLDL-DLH3
nd future events was noted with an OR of 3.15 in the
ighest quartile versus those in the lowest quartile. In a
econd prospective study, Wallenfeldt et al. (113) showed
hat baseline OxLDL-4E6 levels predicted the progression
f carotid intima-media thickness in asymptomatic and
resumably healthy 58-year-old Swedish males, indepen-
ent of other cardiovascular risk factors.
In summary, OxLDL may serve as an attractive biomar-
er as it may provide a link between lipoprotein disorders
nd inflammation. Clinical research on OxLDL biomarkers
s rapidly accelerating, and our understanding of its poten-
ial clinical utility is expanding. However, before such
easures can be incorporated into routine clinical practice,
dditional work is needed to compare the different assays in
heir clinical utility, and more insights are needed into their
bility to provide independent prognostic information, par-
icularly in relation to other risk factors such as LDL-C and
RP. Additionally, more prospective studies are needed
ith serial measurements to assess changes in these markers
ith various treatments.
IPOPROTEIN (a)
ipoprotein (a) is a lipoprotein of unknown physiological
unction composed of apolipoprotein (a) covalently attached
y a single disulfide bond on apolipoprotein B-100 (Fig. 7).
polipoprotein (a) is composed of kringles IV and V and an
nactive protease domain and has high homology (75% to
8%) to plasminogen, which has been postulated to confer
ro-thrombotic effects, although these have been demon-
trated conclusively only in vitro (114,115). Kringle IV is
omposed of 10 subtypes, of which kringle IV-type 2
epeats are very polymorphous and may exist in 2 to 43
opies, whereas the other 9 kringle IV-2 subtypes are
resent in 1 copy. Lipoprotein (a) is transmitted in an
utosomal dominant fashion, and values range from 0 to
ore than 250 mg/dl. Plasma levels are largely determined
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Biomarkers in Vulnerable Patients April 18, 2006:C19–31y the rate of hepatic apoA synthesis, with smaller isoforms
less kringle IV-2 repeats) being secreted much faster than
arger isoforms and therefore resulting in higher plasma
oncentrations. Thus, the number of kringle IV-2 repeats is
oderately inversely related to plasma levels of Lp(a)(114).
ipoprotein (a) concentrations within atherosclerotic le-
ions of saphenous vein grafts have been noted to be
ignificantly higher than plasma levels, suggesting an accu-
ulation in the vessel wall (116).
The association of Lp(a) with CAD and its ability to act as
iomarker of risk appears to be strongest in patients with
Figure 7. Genetic structure of apolipoprotein (a) (top) and structure of lipoypercholesterolemia and, in particular, in young patients with sremature atherosclerosis. Part of the reason for this reflects
he observation that there appear to be important threshold
ffects such that only very high Lp(a) levels are associated with
levated vascular risk; in this regard, increased plasma levels of
p(a) (30 mg/dl) independently predict the presence of
ymptomatic and angiographic CAD, particularly in patients
ith elevated LDL-C levels (117,118). Interestingly, recent
ata from the prospective Cardiovascular Health Study, fol-
owing 3,972 randomly chosen and apparently healthy subjects
65 years old for an average of 7.4 years, showed a relative risk
f approximately three-fold for death from vascular events and
n (a) (bottom). Reprinted, with permission, from Hobbs and White (115).troke in the highest quintile compared to the lowest quintile
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April 18, 2006:C19–31 Biomarkers in Vulnerable Patientsf Lp(a), but for males only, whereas no such relation existed
or women (119). The increased risk appears to be accentuated
n high-risk (120) as opposed to low-risk populations (121),
nd several studies have shown that young patients are partic-
larly affected, compared to older patients (92,122,123).
The underlying mechanisms of Lp(a) contributing to the
athogenesis of atherosclerosis are not well understood. In a
eries of basic (110) and clinical studies (91,92,98,99), we
ave shown that Lp(a) is highly associated with OxPL (r 
0.85 to 90), suggesting that some of its atherogenic
roperties may be mediated by its ability to bind and
ransport OxPL. For example, Lp(a) rises acutely in a
imilar fashion to OxLDL-E06 after ACS (98) and imme-
iately after PCI (99), and correlates with the presence and
xtent of CAD to a similar extent as OxLDL-E06 (92). In
ddition, we have shown that 80 mg atorvastatin increases
p(a) levels 10% from baseline, which has been noted in
everal other studies (reviewed in [91]). In association with
his increase in Lp(a) was an 10% increase in OxLDL-
06 (OxPL/apoB), which we have interpreted as a marker
f efflux of OxPL from the vessel wall and binding of OxPL
y upregulated Lp(a) in the circulation.
Because the excess cardiovascular risk of Lp(a) seems to
bate with lowering LDL-C levels (124) or with aging
92,122,123), it seems most appropriate to focus Lp(a)
valuation to younger patients at high risk, particularly
ales, such as those with multiple risk factors, and partic-
larly those with a family history of premature CAD. When
p(a) levels are elevated (30 mg/dl), the primary objective
s to treat elevated LDL-C or low HDL-C aggressively
ith a statin, perhaps in conjunction with niacin, which is
he only drug that reliably lowers Lp(a) by 30% at the
igher doses. In addition, these types of patients would
resumably derive the greatest benefit from early detection
nd treatment, as Lp(a) levels, except in acute-phase re-
ponse states, remain relatively constant throughout life, and
herefore these patients are exposed to the cardiovascular
isk of Lp(a) starting at birth, similarly to patients with
amilial hypercholesterolemia. Screening for Lp(a) in such
igh-risk individuals would theoretically be cost-effective, as
t needs to be measured only once, but this has not been
valuated as no optimal and specific treatment exists to
ower Lp(a) levels. Use of Lp(a) measurements in low-risk
opulations is not currently recommended.
SOPROSTANES
soprostanes are non-enzymatic, free-radical catalyzed iso-
ers of cyclooxygenase-derived enzymatic products of ara-
hidonic acid (125,126). In contrast to enzymatically gen-
rated prostaglandins, which are generated from free
rachidonic acid, isoprostanes can be generated on intact
holesteryl esters and phospholipids, which are major com-
onents of lipoprotein particles and cell membranes. Fol-
owing generation, isoprostanes are released by a phospho-
ipase activity, circulate in plasma, and are ultimately (xcreted in urine. F2 isoprostanes are stable, specific, and
nique end-products (up to 64 species can be generated) of
ipoprotein metabolism and can be measured with high
ensitivity and specificity with gas chromatography/mass
pectrometry. However, measurement of F2 isoprostanes
oes not necessarily reflect LDL oxidation as they are also
enerated basally at low levels under normal physiological
unctions and are also elevated in most inflammatory dis-
rders.
Elevated F2 isoprostane levels have been documented in
atients with hypercholesterolemia, diabetes mellitus,
moking, renovascular hypertension, and hyperhomocys-
einemia (125,126). Evidence of enhanced presence of F2
soprostanes has been detected within carotid atheroscle-
otic plaques. In addition, they colocalize with foam cells
mmunocytochemically (127), and their levels correlate with
nstable carotid plaques (128). Urinary F2 isoprostane levels
orrelate with plasma LDL-C levels and LDL-associated
soprostanes. Interestingly, unlike in mouse models,
itamin E does not seem to affect urinary isoprostane levels
n humans (129). In addition, isoprostanes are elevated in
nstable angina and in the coronary sinus and urine of
atients undergoing PCI or thrombolysis and reperfusion
uring acute myocardial infarction (125,126).
Measurement of F2 isoprostanes has become the gold
tandard in measuring oxidative stress in vivo. However,
espite the promising clinical data, no prognostic informa-
ion is currently available. In addition, the relative sophis-
ication and expense required to perform isoprostane assays
n specialized laboratories in an efficient and cost-effective
anner inhibits widespread use. Although ELISA kits are
ow available, little information is available to ascertain
heir precision and accuracy, and they are limited by reduced
pecificity in the presence of biological fluids, such as
lasma.
DL PARTICLE SIZE
ETEROGENEITY—SMALL, DENSE LDL
mall, dense LDL is thought be a particularly pro-
therogenic compared to more buoyant LDL because it is
ore amenable to oxidative modification and is easily
ransported to the subendothelial space and trapped by
roteoglycans (130). Small, dense LDL particles are gener-
ted when excess triglycerides on very low-density lipopro-
ein are exchanged for cholesterol esters on LDL by
holesterol ester transfer protein (CETP), producing
riglyceride-rich LDL, which then undergoes lipolysis by
epatic lipase to produce smaller and denser LDL particles.
t least seven subclasses of LDL particles have been
escribed by several techniques, including density gradient
el electrophoresis, ultracentrifugation, and chromato-
raphic and nuclear magnetic resonance spectroscopy tech-
iques based on particle buoyant density (1.019 to 1.060
g/dl), size, charge, and lipid and apoprotein content
130,131). Pattern A represents larger, more buoyant LDL,
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Biomarkers in Vulnerable Patients April 18, 2006:C19–31nd pattern B small, dense LDL, which is present in 30% to
5% of adult males, primarily with metabolic syndrome.
ariations in genes involved in lipoprotein metabolism,
uch as apoA-I, C-III, A-IV, CETP, and manganese-
uperoxide dismutase, may explain 35% to 45% of the
ariability in LDL particle size (132). In addition, dietary fat,
nd particularly increased carbohydrate intake, can induce
mall, dense LDL phenotype (133).
Several prospective and case-control studies have shown
hat small, dense LDL is associated with approximately
hree-fold increased risk of CAD (130,134). In addition,
ngiographic studies have also shown increased CAD pro-
ression in patients with excess small, dense LDL particles.
n the Familial Atherosclerosis Treatment Study, treatment
ith colestipol/lovastatin and colestipol/niacin significantly
ecreased hepatic lipase activity with a concomitant conver-
ion of small, dense LDL to buoyant LDL, which was the
trongest predictor of angiographic regression (135). Simi-
arly, cholestyramine and niacin reduced progression of
ngiographic CAD, but only in those patients with predom-
nantly small, dense LDL (present in 40% of the cohort)
136). However, in most of these and other studies, an
ndependent relationship could not be demonstrated be-
ause of the strong correlation to triglyceride levels. There-
ore, it is debatable whether measuring small, dense LDL at
he current state of the art provides enough additional
linical utility above and beyond measuring triglyceride
evels and/or diagnosing the metabolic syndrome. However,
urther studies are needed to evaluate the predictive value of
ther lipoprotein particles in prospective studies.
ONCLUSIONS
lasma biomarkers are likely to have an important role in
he future in risk stratification and prognosis of cardiovas-
ular disease, particularly when complementing established
isk factors. Compared to invasive or noninvasive imaging
odalities, they offer the advantage of being relatively
isk-free, less expensive, and applicable to a wide range of
opulations at risk. Further, like cholesterol evaluation,
lasma biomarkers can be performed and interpreted in
utpatient primary care settings that are the most appropri-
te for patient follow-up and discussions of preventive
nterventions. However, as they are necessarily measured in
he blood, their tissue or organ etiology often cannot be
etermined and, when abnormal, it may be difficult to
ocalize the site of abnormality. As atherosclerosis is a
iffuse process, plasma biomarkers have the ability to
rovide a general measure of risk that may allow more
argeted assessment with a variety of focused techniques in
hose with abnormal levels. In addition, they may offer a
ore global assessment of the response to therapy to various
nterventions. Coupled with novel imaging modalities,
lasma biomarkers may allow more precise risk stratification
nd prognostication in high-risk populations that may allow
hysicians the ability to intervene sooner in the diseaserocess and reduce mortality and morbidity from cardiovas-
ular disease (137). High-sensitivity C-reactive protein has
lready moved into clinical practice and proven to have
tility in primary prevention, acute coronary ischemia, and
n the monitoring of statin therapy. As described in this
eview, several other biomarkers of inflammation, thrombo-
is, and lipid oxidation are also emerging and may ultimately
rove to have utility in a variety of clinical settings.
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